Gregory Lucier Buys 22,445 Shares of DENTSPLY SIRONA (NASDAQ:XRAY) Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Gregory Lucier purchased 22,445 shares of the stock in a transaction on Tuesday, March 3rd. The shares were purchased at an average price of $14.03 per share, for a total transaction of $314,903.35. Following the transaction, the director directly owned 50,000 shares of the company’s stock, valued at approximately $701,500. This represents a 81.46% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

DENTSPLY SIRONA Price Performance

XRAY opened at $13.44 on Thursday. The stock has a 50-day moving average price of $12.56 and a 200-day moving average price of $12.48. DENTSPLY SIRONA Inc. has a 12-month low of $9.85 and a 12-month high of $17.18. The company has a current ratio of 1.51, a quick ratio of 1.03 and a debt-to-equity ratio of 1.50. The stock has a market capitalization of $2.68 billion, a P/E ratio of -4.48, a PEG ratio of 1.56 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The firm had revenue of $961.00 million for the quarter, compared to analysts’ expectations of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts predict that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were paid a $0.16 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.8%. DENTSPLY SIRONA’s dividend payout ratio is -21.33%.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several institutional investors and hedge funds have recently bought and sold shares of XRAY. Parkside Financial Bank & Trust increased its stake in shares of DENTSPLY SIRONA by 620.6% during the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 1,477 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in DENTSPLY SIRONA in the first quarter worth $26,000. Eurizon Capital SGR S.p.A. bought a new stake in DENTSPLY SIRONA in the fourth quarter valued at $26,000. True Wealth Design LLC raised its holdings in DENTSPLY SIRONA by 273.0% in the 2nd quarter. True Wealth Design LLC now owns 2,376 shares of the medical instruments supplier’s stock worth $38,000 after purchasing an additional 1,739 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its holdings in DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 2,122 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

More DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director purchases: Long‑time director Gregory T. Lucier bought sizable blocks of stock on March 2 and March 3 (27,555 shares at ~$14.24 and 22,445 shares at ~$14.03), raising his ownership to ~50,000 shares — a strong insider confidence signal. InsiderTrades Article
• Positive Sentiment: Barrington Research raised its price target to $17 — an upbeat analyst action that implies meaningful upside relative to current levels and can attract buyer interest. Barrington Research PT Raise
• Positive Sentiment: Zacks upgraded XRAY from “strong sell” to “hold,” removing a negative rating and potentially supporting short‑term sentiment improvement. Zacks Upgrade
• Neutral Sentiment: Mizuho raised its price target to $16 but left a “neutral” rating — modestly positive for price targets but limited catalyst without a rating upgrade. Mizuho Note
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference (Mar 10) — a scheduled event that could provide fresh guidance or color but is not itself a guaranteed catalyst. Conference Notice
• Neutral Sentiment: Fundamental watch‑items: Coverage notes flag international revenue trends and mixed analyst targets (average PT ~$14.42) — useful context for modeling but neither clearly bullish nor bearish on its own. Zacks Analysis
• Neutral Sentiment: Short‑interest reporting appears anomalous (reports showing zero/NaN), so treat any short‑squeeze narratives as unreliable until corrected data is posted.
• Negative Sentiment: Earnings & guidance caveat: The company slightly missed quarterly EPS consensus (by ~$0.01) despite a revenue beat, and FY‑2026 guidance (1.40–1.50 EPS) sits below some sell‑side estimates (~1.84), which could cap upside if analysts lower forecasts. MarketBeat Summary

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Wells Fargo & Company boosted their price target on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Stifel Nicolaus set a $13.00 target price on DENTSPLY SIRONA in a research note on Thursday, November 6th. Robert W. Baird raised their price target on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th. Barrington Research lifted their price target on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Barclays started coverage on DENTSPLY SIRONA in a research note on Monday, December 8th. They set an “underweight” rating and a $12.00 price objective for the company. Three analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $14.42.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.